Form 8-K - Current report:
SEC Accession No. 0001628280-25-034890
Filing Date
2025-07-15
Accepted
2025-07-15 07:54:31
Documents
17
Period of Report
2025-07-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20250715.htm   iXBRL 8-K 27085
2 EX-99.1 aqst-healthcanadaupcomin.htm EX-99.1 14077
6 aqst-healthcanadaupcomin001.jpg GRAPHIC 227903
7 aqst-healthcanadaupcomin002.jpg GRAPHIC 259779
8 aqst-healthcanadaupcomin003.jpg GRAPHIC 302304
9 aqst-healthcanadaupcomin004.jpg GRAPHIC 207177
  Complete submission text file 0001628280-25-034890.txt   1535950

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20250715.xsd EX-101.SCH 1776
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20250715_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20250715_pre.xml EX-101.PRE 12504
19 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20250715_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 251123117
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)